The serum pentraxin-3 is elevated in patients with cardiac syndrome X

ŞEN, Nihat; Kurt, Mustafa; MOTOR, Sedat; BÜYÜKKAYA, Şule; KARAKAŞ, Mehmet Fatih; BÜYÜKKAYA, Eyüp; AKÇAY, Adnan Burak

The serum pentraxin-3 is elevated in patients with cardiac syndrome X

Eyüp BÜYÜKKAYA, (Mustafa Kemal Üniversitesi, Tayfur Ata Sökmen Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Hatay, Türkiye)

Mehmet Fatih KARAKAŞ, (Mustafa Kemal Üniversitesi, Tayfur Ata Sökmen Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Hatay, Türkiye)

Mustafa KURT, (Mustafa Kemal Üniversitesi, Tayfur Ata Sökmen Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Hatay, Türkiye)

Sedat MOTOR, (Mustafa Kemal Üniversitesi, Tayfur Ata Sökmen Tıp Fakültesi, Klinik Biyokimya, Anabilim Dalı, Hatay, Türkiye)

Adnan Burak AKÇAY, (Mustafa Kemal Üniversitesi, Tayfur Ata Sökmen Tıp Fakültesi, Klinik Biyokimya, Anabilim Dalı, Hatay, Türkiye)

Şule BÜYÜKKAYA, (Sağlık Bakanlığı, Antakya Devlet Hastanesi, Kardiyoloji Anabilim Dalı, Hatay, Türkiye)

Nihat ŞEN (Mustafa Kemal Üniversitesi, Tayfur Ata Sökmen Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Hatay, Türkiye)

Türk Kardiyoloji Derneği Arşivi

4 0

Yıl: 2013 Cilt: 41 Sayı: 4 Sayfa Aralığı: 290 - 295 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

The serum pentraxin-3 is elevated in patients with cardiac syndrome X

Öz:

Amaç: Kardiyak sendrom X (KSX), anjina pektoris ve objektif iskemi bulgularına rağmen normal koroner arterlerin saptandığı bir tablodur. KSX ile enflamatuvar belirteçler özellikle de yüksek duyarlıklı C-reaktif protein (hs-CRP) arasındaki ilişki iyi bilinmekte olup pentraksin-3 (PTX-3) ile ilişkisi gösterilmemiştir. Bu çalışmada, PTX-3 ile KSX arasındaki ilişki araştırıldı. Çalışma planı: Çalışmaya koroner arter hastalığı (KAH) şüphesi olan toplam 122 hasta (58 kadın, 64 erkek, ortalama yaş 49.6±5.8 yıl) alındı. İskemi bulgusu (efor testi pozitif 50 hasta, miyokart perfüzyon sintigrafisi pozitif 32 hasta) olan hastalara (toplam 82) koroner anjiyografi yapıldı. Normal koroner anjiyografisi olan hastalar (n=41) KSX grubu ve koroner lezyonu olan hastalar (n=41) KAH grubu olarak kabul edildi. İskemi bulgusu olmayan hastalar kontrol grubuna alındı. Her üç grupta PTX-3 ve hs-CRP düzeyleri araştırıldı. Bulgular: Kardiyak sendrom X grubunda PTX-3 değerleri kontrol grubuna göre yüksek bulundu (0.46±0.16 ve 0.23±0.09 ng/ml, p<0.001). Ancak KSX grubu ile KAH grubu arasında serum PTX-3 ile hs-CRP düzeyleri yönünden anlamlı fark bulunmadı (PTX-3: 0.46±0.16 ve 0.51±0.13 ng/ ml, p=0.21; hs-CRP: 1.04±0.45 ve 1.16±0.64 mg/dl, p=0.62). Kontrol grubunda hs-CRP düzeyi (0.73±0.51 mg/dl), KSX (1.04±0.45 mg/dl) ve KAH (1.16±0.64) grubuna göre anlamlı bir şekilde düşük bulundu (sırasıyla, p=0.03 ve p=0.002). PTX-3 ile hs-CRP arasında pozitif bağıntı olduğu gözlendi (r=0.30, p=0.001). Sonuç: Pentraksin-3 yeni bir enflamatuvar belirteç olup, KSX’li hastalarda iyi bilinen enflamatuvar belirteçlerden olan hs-CRP gibi yükselmektedir. PTX-3, KSX’li hastalarda enflamatuvar durumu yansıtan bir biyobelirteç olabilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Kemp HG Jr. Syndrome X revisited. J Am Coll Cardiol 1991;17:507-8.
2. Kemp HG, Kronmal RA, Vlietstra RE, Frye RL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 1986;7:479-83.
3. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993;328:1659-64.
4. Quyyumi AA, Cannon RO 3rd, Panza JA, Diodati JG, Epstein SE. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation 1992;86:1864-71.
5. Vane JR, Anggård EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
6. Tousoulis D, Davies GJ, Asimakopoulos G, Homaei H, Zouridakis E, Ahmed N, et al. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol 2001;24:301-4.
7. Cosín-Sales J, Pizzi C, Brown S, Kaski JC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol 2003;41:1468-74.
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
9. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001;54:316-22.
10. Fazzini F, Peri G, Doni A, Dell’Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841-50.
11. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-41.
12. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-54.
13. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001;29:1404-7.
14. Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006;18:415-23.
15. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-7.
16. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81.
17. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011;57:861-9.
18. Saygı S, Kırılmaz B, Tengiz İ, Türk UÖ, Yıldız H, Tuzun N, et al. Long pentraxin-3 measured at late phase associated with GRACE risk scores in patients with non-ST elevation acute coronary syndrome and coronary stenting. Turk Kardiyol Dern Ars 2012;40:205-12.
19. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J 2012;163:274-9.
20. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006;45:326-30.
21. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate im- munity. Immunol Rev 2009;227:9-18.
22. Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010;210:220- 5.
23. Sen N, Poyraz F, Tavil Y, Yazici HU, Turfan M, Hizal F, et al. Carotid intima-media thickness in patients with cardiac syndrome X and its association with high circulating levels of asymmetric dimethylarginine. Atherosclerosis 2009;204:e82- 5.
24. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-6.
25. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;215:48-55.
26. Jaillon S, Peri G, Delneste Y, Frémaux I, Doni A, Moalli F, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007;204:793-804.
27. Inforzato A, Baldock C, Jowitt TA, Holmes DF, Lindstedt R, Marcellini M, et al. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J Biol Chem 2010;285:17681-92.
28. Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez- Correa G, Bottazzi B, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005;25:1837-42.

APA	BÜYÜKKAYA E, KARAKAŞ M, Kurt M, MOTOR S, AKÇAY A, BÜYÜKKAYA Ş, ŞEN N (2013). The serum pentraxin-3 is elevated in patients with cardiac syndrome X. , 290 - 295.
Chicago	BÜYÜKKAYA Eyüp,KARAKAŞ Mehmet Fatih,Kurt Mustafa,MOTOR Sedat,AKÇAY Adnan Burak,BÜYÜKKAYA Şule,ŞEN Nihat The serum pentraxin-3 is elevated in patients with cardiac syndrome X. (2013): 290 - 295.
MLA	BÜYÜKKAYA Eyüp,KARAKAŞ Mehmet Fatih,Kurt Mustafa,MOTOR Sedat,AKÇAY Adnan Burak,BÜYÜKKAYA Şule,ŞEN Nihat The serum pentraxin-3 is elevated in patients with cardiac syndrome X. , 2013, ss.290 - 295.
AMA	BÜYÜKKAYA E,KARAKAŞ M,Kurt M,MOTOR S,AKÇAY A,BÜYÜKKAYA Ş,ŞEN N The serum pentraxin-3 is elevated in patients with cardiac syndrome X. . 2013; 290 - 295.
Vancouver	BÜYÜKKAYA E,KARAKAŞ M,Kurt M,MOTOR S,AKÇAY A,BÜYÜKKAYA Ş,ŞEN N The serum pentraxin-3 is elevated in patients with cardiac syndrome X. . 2013; 290 - 295.
IEEE	BÜYÜKKAYA E,KARAKAŞ M,Kurt M,MOTOR S,AKÇAY A,BÜYÜKKAYA Ş,ŞEN N "The serum pentraxin-3 is elevated in patients with cardiac syndrome X." , ss.290 - 295, 2013.
ISNAD	BÜYÜKKAYA, Eyüp vd. "The serum pentraxin-3 is elevated in patients with cardiac syndrome X". (2013), 290-295.

APA	BÜYÜKKAYA E, KARAKAŞ M, Kurt M, MOTOR S, AKÇAY A, BÜYÜKKAYA Ş, ŞEN N (2013). The serum pentraxin-3 is elevated in patients with cardiac syndrome X. Türk Kardiyoloji Derneği Arşivi, 41(4), 290 - 295.
Chicago	BÜYÜKKAYA Eyüp,KARAKAŞ Mehmet Fatih,Kurt Mustafa,MOTOR Sedat,AKÇAY Adnan Burak,BÜYÜKKAYA Şule,ŞEN Nihat The serum pentraxin-3 is elevated in patients with cardiac syndrome X. Türk Kardiyoloji Derneği Arşivi 41, no.4 (2013): 290 - 295.
MLA	BÜYÜKKAYA Eyüp,KARAKAŞ Mehmet Fatih,Kurt Mustafa,MOTOR Sedat,AKÇAY Adnan Burak,BÜYÜKKAYA Şule,ŞEN Nihat The serum pentraxin-3 is elevated in patients with cardiac syndrome X. Türk Kardiyoloji Derneği Arşivi, vol.41, no.4, 2013, ss.290 - 295.
AMA	BÜYÜKKAYA E,KARAKAŞ M,Kurt M,MOTOR S,AKÇAY A,BÜYÜKKAYA Ş,ŞEN N The serum pentraxin-3 is elevated in patients with cardiac syndrome X. Türk Kardiyoloji Derneği Arşivi. 2013; 41(4): 290 - 295.
Vancouver	BÜYÜKKAYA E,KARAKAŞ M,Kurt M,MOTOR S,AKÇAY A,BÜYÜKKAYA Ş,ŞEN N The serum pentraxin-3 is elevated in patients with cardiac syndrome X. Türk Kardiyoloji Derneği Arşivi. 2013; 41(4): 290 - 295.
IEEE	BÜYÜKKAYA E,KARAKAŞ M,Kurt M,MOTOR S,AKÇAY A,BÜYÜKKAYA Ş,ŞEN N "The serum pentraxin-3 is elevated in patients with cardiac syndrome X." Türk Kardiyoloji Derneği Arşivi, 41, ss.290 - 295, 2013.
ISNAD	BÜYÜKKAYA, Eyüp vd. "The serum pentraxin-3 is elevated in patients with cardiac syndrome X". Türk Kardiyoloji Derneği Arşivi 41/4 (2013), 290-295.